ArticleCellular immunology2011
Melanoma-induced suppression of tumor antigen-specific T cell expansion is comparable to suppression of global T cell expansion.
Article in Cellular immunology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 11 citations in OpenAlex.
- Spatiotemporal local and abscopal cell death and immune responses to histotripsy focused ultrasound tumor ablation.Frontiers in immunology · 2023Article
- Japanese Kampo Medicine Juzentaihoto Improves Antiviral Cellular Immunity in Tumour-Bearing Hosts.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Systemic immunity in cancer.Nature reviews. Cancer · 2021Review
- Systemic dysfunction and plasticity of the immune macroenvironment in cancer models.Nature medicine · 2020Article
- Non-thermal histotripsy tumor ablation promotes abscopal immune responses that enhance cancer immunotherapy.Journal for immunotherapy of cancer · 2020Article
- Co-transfer of tumor-specific effector and memory CD8+ T cells enhances the efficacy of adoptive melanoma immunotherapy in a mouse model.Journal for immunotherapy of cancer · 2018Article
- Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.Cancer immunology, immunotherapy : CII · 2016Article
- Memory T cells are uniquely resistant to melanoma-induced suppression.Cancer immunology, immunotherapy : CII · 2013Article
- Cellular and cytokine-dependent immunosuppressive mechanisms of grm1-transgenic murine melanoma.Cancer immunology, immunotherapy : CII · 2012Article
- Ctla-4 blockade plus adoptive T-cell transfer promotes optimal melanoma immunity in mice.Journal of immunotherapy (Hagerstown, Md. : 1997)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
We have observed that in vivo interaction between melanoma and resting T cells promotes suppression of antigen-driven proliferative T cell expansion. We hypothesized that this suppression would affect tumor antigen-specific T cell populations more potently than tumor-unrelated T cell populations. A B16F10 cell line was stably transfected to express low levels of the lymphocytic choriomeningitis virus (LCMV) glycoprotein GP33 (B16GP33). Mice bearing B16F10 or B16GP33 tumors were infected with LCMV, and proliferative expansion of LCMV epitope-specific T cell populations was quantified. In vitro and in vivo assays confirmed low levels of antigenic GP33 expression by B16GP33 tumors. Suppressed expansion of GP33-specific T cells was equivalent between mice bearing B16F10 and B16GP33 tumors. These observations suggest that the ability of growing melanoma tumors to impair antigen-driven proliferative expansion of activated T cells is global and not antigen-specific, and provide further insight into the influence of cancer on activated T cell homeostasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.